eligibility_summary
Adults ≥18 with RRMM/RRpPCL and measurable disease, prior PI, IMiD, anti‑CD38 (RRMM), refractory, ≥PR once, RRpPCL ≥1 prior line. ECOG 0–1, >12‑wk L/E, adequate organ fxn, can stop therapy for apheresis, contraception. Exclude: preg/lactation, HIV/HBV/HCV or active infxn, prior anti‑GPRC5D, unresolved AEs, recent auto (<12w)/allo (<6m) SCT or GvHD, recent steroids/live vax/surgery, cardiopulmonary dz or O2, active autoimmune dz, other cancer, CNS dz or stroke/seizure <6m, allergy to study drugs.
trial_source
clinical_trials.gov from Dec 2, 2025
annotation_status
ai
ai_summary
Intervention: CT071, an autologous anti‑GPRC5D CAR‑T cell therapy (biological, genetically modified patient T cells). Mechanism of action: T cells are engineered to express a chimeric antigen receptor that recognizes GPRC5D on malignant plasma cells, upon antigen engagement, CAR‑T cells activate, proliferate, release cytokines, and kill target cells. Administration: lymphodepletion followed by a single CT071 infusion. Targets: GPRC5D on clonal plasma cells in RR multiple myeloma and RR primary plasma cell leukemia, engages T‑cell cytotoxic pathways against tumor cells. Phase 1/2, dose escalation/expansion to RP2D, then single‑arm.